[Adverse effects of high-dose methotrexate therapy].

Objective: To investigate the adverse effects of high-dose methotrexate (HDMTX) therapy, and to provide a theoretical basis for optimizing clinical treatment.

Methods: A retrospective analysis was performed for the clinical data of 120 children with acute lymphoblastic leukemia or non-Hodgkin lymphoma who underwent 601 times of HDMTX therapy. The adverse effects of various systems were analyzed according to the WHO criteria for the classification of adverse effects of anticancer drugs.

[Autoimmune lymphoproliferative syndrome: a case report and literature review].

We described 1 case of autoimmune lymphoproliferative syndrome (ALPS), first diagnosed in our hospital, and reviewed the recent literature. The 11-month old male patient presented with a history of splenomegaly and hepatomegaly since 1 month after birth. He suffered recurrent infectious diseases including cytomegalovirus infection, parvovirus B19 infection and chronic diarrhea disease.

[Therapeutic strategies for childhood high-risk acute lymphoblastic leukemia].

Contemporary treatments have resulted in 5-year event-free survival rates (EFS) of approximately 75% to 80% for childhood acute lymphoblastic leukemia (ALL). Relapses of ALL in children were more often in HR-ALL but also in very few non-HR-ALL. Thus current clinical study of ALL has focused on improving the outcome of a few subtypes of HR-ALL.

[Investigation on individualized adjustment of target range of high-dose methotrexate].

Objective: To explore the way of individualized adjustment of target range of each high-dose methotrexate (MTX) 24 hours infusion to treat acute lymphoblastic leukemia in children.

Methods: Twenty-four children and 105 infusions were included in the study. According to 1 h and 6 h plasma MTX concentrations after infusion, based on established high-dose MTX population pharmacokinetics model, the course predicted value of drug concentration at steady state (C(SS)) was calculated.

[Nonmuscle myosin heavy chain 9 gene mutations related disease: a family report].

Objective: To improve the recognition of nonmuscle myosin heavy chain 9 gene (MYH9) mutations related disease.

Methods: Clinical information and laboratory data of a family of MYH9-related disease was reported. Cytomorphology examination of peripheral blood and bone marrow smears were stained with Wright-Giemsa stain.